(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 September 2012 (13.09.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/120328 A1

(51) International Patent Classification:
A61K 31/444 (2006.01) *A61K 9/48* (2006.01)
A61K 9/107 (2006.01) *A61K 9/08* (2006.01)
A61K 9/14 (2006.01)

(21) International Application Number:
PCT/IB2011/001842

(22) International Filing Date:
10 August 2011 (10.08.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1103860.1 7 March 2011 (07.03.2011) GB

(71) Applicant *(for all designated States except US)*: **NATCO PHARMA LIMITED** [IN/IN]; Natco House, Road No. 2, Banjara Hills, Hyderabad 500 033, Andhra Pradesh (IN).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PARVATANENI, Durga maheswari** [IN/IN]; NATCO PHARMA LIMITED, NATCO HOUSE, ROAD NO.2, BANJARA HILLS, HYDERABAD, ANDHRA PRADESH 500033 (IN). **YEDLURI, Siddhartha** [IN/IN]; NATCO PHARMA LIMITED, NATCO HOUSE, ROAD NO.2, BANJARA HILLS, HYDERABAD, ANDHRA PRADESH 500033 (IN). **APPADWEDULA, Venkata Satyanarayana** [IN/IN]; NATCO PHARMA LIMITED, NATCO HOUSE, ROAD NO.2, BANJARA HILLS, HYDERABAD, ANDHRA PRADESH 500033 (IN). **ADIBHATLA, Kali Satya Bhujanga Rao** [IN/IN]; NATCO PHARMA LIMITED, NATCO HOUSE, ROAD NO.2, BANJARA HILLS, HYDERABAD, ANDHRA PRADESH 500033 (IN). **NANNAPANENI, Venkaiah Chowdary** [IN/IN]; NATCO PHARMA LIMITED, NATCO HOUSE, ROAD NO.2, BANJARA HILLS, HYDERABAD, ANDHRA PRADESH 500033 (IN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

WO 2012/120328 A1

(54) **Title**: FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT

(57) **Abstract**: An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs such as Form I, Form II and Form III thereof to improve the bioavailability intended for self-emulsification upon its contact with the gastro-intestinal fluid. The invention also relates to a process for the preparation of oral solution containing NRC-AN-019 in an effective concentration for the better therapy against Chronic Myeloid Leukemia as BCR-ABL tyrosine kinase inhibitor and against other tumors such as head and neck cancer, prostate cancer and the like.